Join?Arizona Liver Health?as we bring you the latest advancements and key takeaways from AASLD's?The Liver Meeting 2024.?Engage with our experts as they present cutting-edge insights and host a live Q&A session. This event is designed for all medical professionals, including MDs, DOs, NPs, PAs, MAs, CRCs, and anyone passionate about liver disease prevention, care, and treatment. Date:?December 4, 2024 Reception:?5:30 PM Program:?6:00 PM Where:?Seasons 52 2502 E Camelback Rd. Phoenix, AZ 85016 Topics We'll Cover: -MASLD/MASH -PBC/PSC -Viral Hepatitis & Cirrhosis Space is limited—RSVP today to secure your spot! RSVP by emailing Anne Payne at?[email protected]?or click here:?bit.ly/124dinnerrsvp Anita Kohli Naim Alkhouri, MD, FAASLD Richard Manch Rida Nadeem, MD, MSPH Tessa Janovsky Yessica Sachdeva Angie Coste Esteban Rafael Lugo Morales Reichard R. Michelle Jones Kelly Black Nick Engelke Dylan Moore Madrigal Pharmaceuticals Fortrea Novo Nordisk Ipsen, Akero Therapeutics, Echosens, Gilead Sciences, AbbVie, Eli Lilly and Company, Boston Pharmaceuticals, 89bio, GSK, Summit Clinical Research, Fatty Liver Alliance, Michael Betel, Mazen Noureddin, MD, MHSc,
关于我们
Arizona Liver Health is a clinical practice and research institute that provides specialized diagnostics, evaluation, treatment and clinical trial access for patients with fatty liver disease and other liver conditions.
- 网站
-
https://www.azliver.com
Arizona Liver Health的外部链接
- 所属行业
- 医疗机构
- 规模
- 51-200 人
- 总部
- Chandler
- 类型
- 合营企业
- 领域
- FibroScan、hepatology、fatty liver、NASH、NAFLD、Liver Disease、Metabolic、Autoimmune和Cirrhosis
地点
Arizona Liver Health员工
-
Carrie Tye
Payroll and Benefits Administration
-
Michelle Jones
Business Development, Operations & Growth Executive ● Strategic Vision ● Marketing Leadership ● Operational Transformation ● Revenue Growth
-
Angie Coste
Phase 1 Clinical Research Director
-
John Raslavsky
Sr. Web Designer (WordPress) and Software Education Co-Ordinator @ Arizona Liver Health
动态
-
Humanitarian efforts often go unnoticed, especially in outreach programs like those at VEN Centers. Supporting the unhoused population—who often lack access to basic necessities like food, water, and medical care—requires a unique level of compassion and dedication. In this video, hear firsthand from two of our incredible Outreach Specialists, Edgar Lizarraga and Alejandra Castro Beltran, as they share what their roles mean to them. Anita Kohli Naim Alkhouri, MD, FAASLD Richard Manch Dylan Moore Brennin Palfrey Kylee Newgass Yessica Sachdeva Rida Nadeem, MD, MSPH Gavin Ferguson Tiffany Hendrix Colleen Hopkins Michelle Guffey Michelle Jones Kelly Black Nick Engelke Anne Payne Desirae Trotter
-
Join Us for a Post-AASLD Liver Update! Arizona Liver Health invites you to an exclusive event where we'll share the latest insights from #TheLiverMeeting2024. Date:?December 4, 2024 Reception:?5:30 PM Program:?6:00 PM Location:?Seasons 52, 2502 E Camelback Rd., Phoenix, AZ 85016 Topics Include: MASLD/MASH PBC/PSC Viral Hepatitis & Cirrhosis This event is open to all medical professionals—MDs, DOs, NPs, PAs, MAs, CRCs, and more—interested in liver health care and treatment. Space is limited—RSVP today to secure your spot! RSVP by emailing Anne Payne at?[email protected] or click here: https://lnkd.in/g_RXFYHt Naim Alkhouri, MD, FAASLD Anita Kohli Richard Manch Yessica Sachdeva Rida Nadeem, MD, MSPH Tessa Janovsky Angie Coste Esteban Rafael Lugo Morales Reichard R. Michelle Jones Kelly Black Nick Engelke Dylan Moore Madrigal Pharmaceuticals Fortrea Novo Nordisk Ipsen, Akero Therapeutics, Echosens, Gilead Sciences, AbbVie, Eli Lilly and Company, Boston Pharmaceuticals, 89bio, GSK, Summit Clinical Research, Fatty Liver Alliance, Michael Betel, Mazen Noureddin, MD, MHSc,
-
Dr. Naim Alkhouri delivered an insightful presentation on Treatment of MetALD: Challenges and Opportunities, shedding light on the growing complexity of metabolic dysfunction- and alcohol-associated liver disease (MetALD). Key takeaways included: *The rise of the Steatologist, a specialist in hepatology, addiction medicine, and obesity medicine, enhanced with tools like prescription digital therapeutics for lifestyle and mental health support. *Evidence that MetALD is associated with higher rates of fibrosis and metabolic-associated liver outcomes (MALOs) compared to MASLD, as shown in Swedish cohort studies and U.S. transplant data. *Promising efficacy of resmetirom in MetALD patients, as seen in the MAESTRO-NASH trial, highlighting its potential in treatment strategies. Dr. Alkhouri emphasized the urgent need for trial designs to address MetALD specifically and for inclusion of MetALD patients in broader MASH research. This important work continues to drive innovation in liver health care and research. #LiverHealth #MetALD #MASLD #ClinicalResearch #AASLD Naim Alkhouri, MD, FAASLD, Anita Kohli, Richard Manch, Yessica Sachdeva, Tessa Janovsky Rida Nadeem, MD, MSPH Michelle Jones Kelly Black Nick Engelke, American Association for the Study of Liver Diseases (AASLD), Fatty Liver Alliance, Mazen Noureddin, MD, MHSc, Angie Coste Novo Nordisk Boehringer Ingelheim Madrigal Pharmaceuticals Fortrea Ipsen, Akero Therapeutics, Echosens, Gilead Sciences, AbbVie, Eli Lilly and Company, Boston Pharmaceuticals, 89bio, GSK, Summit Clinical Research
Treatment of MetALD: Challenges and Opportunities presented by Naim Alkhouri, MD, FAASLD. What is a Steatologist?? The SLD Doctor (Steatologist): ? Qualification: fellowship that combines outpatient hepatology, addiction medicine, and obesity medicine Board-certification. ? Enhanced with prescription digital therapeutics for mental health and healthy lifestyle interventions. Trial Design for MetALD: MetALD Is Associated with Higher Rates of MALO ? A register-based cohort study of 15,107 patients with a diagnosis of MASLD in Sweden between 1987 and 2020 (median follow up 5.2 years). Patients with diagnosed ALD or AUD after MASLD diagnosis had almost 6-fold risk of incident MALOS (aHR; 95% Cl 4.90-6.88). MetALD is a Common Cause of LTx in the US A retrospective study using the US United Network for Organ Sharing registry. Between 2002 and 2022, waitlist registrations and transplants for MetALD increased 2.9-fold and 3.3-fold, respectively. Resmetirom Study Conclusions * A total of 75 (9.6%) of patients had possible MetALD during the first 52 weeks of MAESTRO-NASH. * Baseline characteristics showed more males; higher mean AST, CDT, GGT levels, and higher mean FIB-4 score; and fewer patients with T2DM in the MetALD versus low alcohol group. * Response rates to resmetirom in patients with suspected MetALD were similar to those without MetALD. Take Home Message * MetALD is associated with higher rates of steatohepatitis, significant fibrosis, and MALOs than MASLD. * There is an urgent need to design future trials for MetALD AND to include MetALD patients in MASH trials.?Resmetirom showed promising efficacy results in MetALD. American Association for the Study of Liver Diseases (AASLD), Arizona Liver Health, Michelle Jones
-
+3
-
Don’t miss this in-depth session at #AASLD #TheLiverMeeting2024 in San Diego on?Metabolic Dysfunction-Associated and Alcohol-Associated Liver Disease (MetALD)! Expert speakers will explore key topics, with individual breakouts, followed by a panel discussion: MetALD Unveiled: Understanding Definition and Epidemiology Presented by:?Danielle Brandman, MD, MAS, FAASLD ?? Nov 18, 4:00 PM - 4:10 PM,?Convention Center:?Room 24 Diagnosing MetALD: New Perspectives and Approaches Presented by:?Douglas A. Simonetto, MD ?? Nov 18, 4:10 PM - 4:20 PM,?Convention Center:?Room 24 Treatment of MetALD: Challenges and Opportunities Presented by:?Naim Alkhouri, MD ?? Nov 18, 4:20 PM - 4:35 PM,?Convention Center:?Room 24 Join us for a comprehensive look at MetALD—issues, insights, and emerging treatment approaches! Naim Alkhouri, MD, FAASLD Danielle Brandman, Doug Simonetto, Meena Bansal, Bilal Hameed, Anita Kohli, Michelle Jones,?Yessica Sachdeva,?Richard Manch,?Angie Coste,?Brett Lantz?Chelsea Ann Mihaylo Hum, PMP?Kelly Carey Rida Nadeem, MD, MSPH Esteban Rafael Lugo Morales??Kelly Black?Nick Engelke?Dylan Moore?Madrigal Pharmaceuticals?Fortrea?Novo Nordisk?Ipsen,?Akero Therapeutics,?Echosens,?Gilead Sciences,?AbbVie,? Eli Lilly and Company,?Boston Pharmaceuticals,?89bio,?GSK,?Summit Clinical Research,?Fatty Liver Alliance,?Michael Betel,?Gilead Sciences,?Mazen Noureddin, MD, MHSc,?Rohit Loomba,?Jeffrey V. Lazarus,?Justin A. Reynolds, MD,?J?rn M. Schattenberg,?Jacqueline O'Leary, MD MPH
-
The American Association for the Study of Liver Diseases (AASLD)The Liver Meeting was alive with sessions, poster presentations, the opening of the exhibit hall and several product theater presentations yesterday! One of the product theater presentations examined MASH and the role of cardiometabolic dysfunction in disease development and progression. The discussion centered around AASLD guidelines regarding screening and management of patients at high-risk for advanced disease presented by Dr. Naim Alkhouri, MD, FAASLD and supported by industry partner Novo Nordisk. #AASLD #TLM24 #MASH #ALH #ACT Anita Kohli Richard Manch Tessa Janovsky Rida Nadeem, MD, MSPH Michelle Jones Kelly Black Nick Engelke Mazen Noureddin, MD, MHSc Fatty Liver Alliance Jeffrey V. Lazarus
-
Dr. Naim Alkhouri will be presenting on “Treatment of MetALD: Challenges and Opportunities” during the panel on Metabolic Dysfunction-Associated and Alcohol-Associated Liver Disease (MetALD) at #AASLD #TheLiverMeeting. Location:?Convention Center:?Room 24 When: November 18, 2024, 4:10PM-4:20PM See you there! Anita Kohli, Naim Alkhouri, MD, FAASLD, Yessica Sachdeva, Richard Manch, Ann Moore, Angie Coste, Brett Lantz Chelsea Ann Mihaylo Hum, PMP Kelly Carey Novemi Alejandro Rida Nadeem, MD, MSPH Esteban Rafael Lugo Morales Michelle Jones Kelly Black Nick Engelke Dylan Moore Madrigal Pharmaceuticals Fortrea Novo Nordisk Ipsen, Akero Therapeutics, Echosens, Gilead Sciences, AbbVie, Eli Lilly and Company, Boston Pharmaceuticals, 89bio, GSK, Summit Clinical Research, Fatty Liver Alliance, Michael Betel, Gilead Sciences, Mazen Noureddin, MD, MHSc, Meena Bansal, Rohit Loomba, Jeffrey V. Lazarus, Justin A. Reynolds, MD, J?rn M. Schattenberg, Jacqueline O'Leary, MD MPH
-
A full house at this evening's CME symposium,?“The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care,”?featuring Dr. Naim Alkhouri, Dr. Amreen Dinani, and Dr. Nicholas Pennings. (This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc.) Naim Alkhouri, MD, FAASLD, Amreen Dinani, Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP, Anita Kohli, Michelle Jones, Richard Manch, Yessica Sachdeva, Nick Engelke, Kelly Black, American Association for the Study of Liver Diseases (AASLD), Fatty Liver Alliance, Mazen Noureddin, MD, MHSc, Meena Bansal, Angie Coste Novo Nordisk Boehringer Ingelheim
-
Arizona Liver Health is excited to feature Dylan Moore, Director of VEN Centers, presenting at #AASLD's The Liver Meeting 2024! Topic:?The Role of Advanced Practice Providers in HCV and MASLD – Rapid Start-Up of a Field-Based Hepatitis C Elimination Program Enabled by State-Funded 340B Initiative Date/Time:?November 17, 2024, 5:00 PM - 5:15 PM Location:?Ballroom 6F Join us to hear insights from Dylan on innovative approaches in hepatitis C elimination! #LiverHealth #HCV #MASLD Anita Kohli,?Naim Alkhouri, MD, FAASLD,?Yessica Sachdeva,?Richard Manch,?Ann Moore,?Angie Coste,?Brett Lantz?Chelsea Ann Mihaylo Hum, PMP?Kelly Carey?Novemi Alejandro?Rida Nadeem, MD, MSPH,?Esteban Rafael Lugo Morales?Michelle Jones?Kelly Black?Nick Engelke?Dylan Moore?Madrigal Pharmaceuticals?Fortrea?Novo Nordisk?Ipsen,?Akero Therapeutics,?Echosens,?Gilead Sciences,?AbbVie,?Eli Lilly and Company,?Boston Pharmaceuticals,?89bio,?GSK,?Summit Clinical Research,?Fatty Liver Alliance,?Michael Betel,?Gilead Sciences,?Mazen Noureddin, MD, MHSc,?Meena Bansal,?Rohit Loomba,?Jeffrey V. Lazarus,?Justin A. Reynolds, MD,?Jacqueline O'Leary, MD MPH
-
Don’t miss this insightful session as Dr. Manch discusses innovative strategies for achieving Hepatitis C elimination through pharmacist-led initiatives! Arizona Liver Health is proud to highlight Dr. Richard Manch’s presentation at #AASLD's The Liver Meeting 2024! Topic:?Capacity Building and Advocacy for Hepatitis C Virus Elimination Session:?U.S. Pharmacist-Based Hepatitis C Virus Elimination Program Time:?Nov. 17, 10:05 AM - 10:15 AM Location:?Room 23 #LiverHealth #HepatitisC #AASLD Anita Kohli,?Naim Alkhouri, MD, FAASLD,?Yessica Sachdeva,?Richard Manch,?Ann Moore,?Angie Coste,?Brett Lantz?Chelsea Ann Mihaylo Hum, PMP?Kelly Carey?Novemi Alejandro?Rida Nadeem, MD, MSPH Rida Nadeem, MD, MSPH, Esteban Rafael Lugo Morales? Michelle Jones?Kelly Black?Nick Engelke?Dylan Moore?Madrigal Pharmaceuticals?Fortrea?Novo Nordisk?Ipsen,?Akero Therapeutics,?Echosens,?Gilead Sciences,?AbbVie,?Eli Lilly and Company,?Boston Pharmaceuticals,?89bio,?GSK,?Summit Clinical Research,?Fatty Liver Alliance,?Michael Betel,?Gilead Sciences,?Mazen Noureddin, MD, MHSc,?Meena Bansal,?Rohit Loomba,?Jeffrey V. Lazarus,?Justin A. Reynolds, MD,?J?rn M. Schattenberg,?Jacqueline O'Leary, MD MPH